IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

NCT06119685 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

NHL
Multiple Myeloma
Blood Cancer
Refractory Non-Hodgkin Lymphoma
Relapsed Non-Hodgkin Lymphoma
Refractory Multiple Myeloma
Relapsed Multiple Myeloma

Interventions

DRUG: IDP-023
DRUG: Rituximab
DRUG: Daratumumab
DRUG: Interleukin-2
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Mesna
DRUG: Isatuximab

Sponsor

Indapta Therapeutics, INC.